NCT03264989 - Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

June 26, 2023

Study Completion Date

June 26, 2023

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG

crizanlizumab

Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days

Trial Locations (12)

10467

Childrens Hospital at Montefiore, The Bronx

21201

University of Maryland Medical Ctr, Baltimore

27710

Duke University Medical Center Patient Treatment, Durham

27858

East Carolina University East Carolina University, Greenville

29203

M Francisco Gonzalez MD PA ., Columbia

29425

Medical Uni of South Carolina Medical Univ of SC, Charleston

29732

Carolina Blood and Cancer Care of South Carolina, Rock Hill

30342

Childrens Healthcare of Atlanta ., Atlanta

30912

Augusta University Georgia Patient Treatment, Augusta

32763

Novartis Investigative Site, Orange

33606

Novartis Investigative Site, Tampa

19104-4399

Childrens Hospital Of Philadelphia Patient Treatment, Philadelphia